Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | MLYCD | O95822 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003735 | 0.92 | TP53 (0.68) | HPGDALDH1A1GAAMAPTHDAC1 | |
| SCHEMBL11212992 | 0.92 | HPGD (0.72) | HPGDALDH1A1GAAMAPTHDAC1 | |
| SCHEMBL1005865 | 0.89 | HPGD (0.82) | HPGDALDH1A1GAAMAPTHDAC1 | |
| SCHEMBL2614245 | 0.89 | HPGD (0.71) | HPGDALDH1A1GAAMAPTHDAC1 | |
| SCHEMBL72112 | 0.88 | HPGD (0.85) | HPGDALDH1A1GAAMAPTHDAC1 | |
| SCHEMBL6919327 | 0.87 | HPGD (0.74) | HPGDALDH1A1GAAMAPTHDAC1 | |
| SCHEMBL1003828 | 0.87 | HPGD (0.66) | HPGDALDH1A1GAAMAPTHDAC1 | |
| SCHEMBL11213668 | 0.87 | HPGD (0.69) | HPGDALDH1A1GAAMAPTHDAC1 | |
| Hydrochloric Acid SCHEMBL8527466 | 0.86 | HPGD (0.81) | HPGDALDH1A1GAAMAPTHDAC1 | |
| Hydrochloric Acid SCHEMBL6612619 | 0.86 | HPGD (0.81) | HPGDALDH1A1GAAMAPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | claimed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | claimed |
| EP-1678146-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | claimed |
| WO-2005040133-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-05-06 | — | — | WO | claimed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| US-20220177416-A1 | PREPARING METHOD OF COMPOUNDS INCLUDING AMIDE GROUP FROM TERTIARY AMINE | Research & Business Foundation Sungkyunkwan University (KR) | 2022-06-09 | — | — | US | disclosed |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | PFIZER INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007103456-A2 | PIPERAZINE AND PIPERIDINE BIARYL DERIVATIVES | TRIMERIS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1678164-B1 | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177416-A1 | PREPARING METHOD OF COMPOUNDS INCLUDING AMIDE GROUP FROM TERTIARY AMINE | TYR, NAT1, SAT1 | HPGD 3544/4885ALDH1A1 2021/4885GAA 1094/4885 |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | HPGD 1845/4885ALDH1A1 846/4885GAA 3532/4885 |
| US-20070225291-A1 | Substituted Pyrazinone Compounds for the Treatment of Inflammation | CNKSR1, IL1RN, CHUK | HPGD 1046/4885ALDH1A1 945/4885GAA 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.